Reviewed July 28, 2026
Is MOTS-c Legal? FDA Status and Licensed Care Options
A committee recommendation is not FDA approval. Here is exactly what changed, and what did not.
The short answer
- FDA status
- Not an FDA-approved drug product
- July 2026 vote
- Advisory committee recommended for the 503A bulks list process
- Reviewed for
- Obesity and osteoporosis
- Prescriber
- Required. Available only through a licensed clinician.
The committee recommended this compound continue in the process that could allow licensed 503A pharmacies to compound it. The FDA has not acted yet. It is not an approved drug, and a recommendation is not permission to purchase it.
Why “is it legal” has no yes-or-no answer
For peptides, access is not a single switch. It depends on the FDA status of the substance, whether a compounding pathway applies, what your state’s pharmacy and medical boards permit, and whether a licensed clinician has evaluated you and written a prescription. Any source giving you a flat yes or no is skipping at least three of those.
MOTS-c sits closest to the weight-loss market, which makes it the compound most likely to be pitched to people who lost access to a compounded GLP-1 prescription. If you arrived here after that kind of disruption, this is the page where the distinction matters most.
What the advisory committee actually reviewed
The committee reviewed MOTS-c in the context of obesity and osteoporosis. Being reviewed for an obesity context is not the same as being an established weight-loss treatment, and it is not a substitute for a GLP-1 medication a clinician previously prescribed. It is also not a longevity or metabolic-optimization endorsement, which is how it is most often marketed.
A regulatory vote is not a longevity or energy promise.
What a committee recommendation is — and is not
The Pharmacy Compounding Advisory Committee advises the FDA. Its recommendations can shape what the agency does next, but the FDA is not required to follow them, and a recommendation is not a drug approval, a safety finding, a prescription, or proof that any clinic can offer something today. The FDA meeting record and the 503A bulk drug substances page are the authoritative sources.
Questions people ask
Is MOTS-c a replacement for compounded semaglutide or tirzepatide?
No. They are different compounds with different regulatory positions and different evidence. If your prescription ended, the next step is a licensed clinician who can review your situation - not a substitution you make yourself.
What did the committee decide about MOTS-c?
It recommended MOTS-c continue in the 503A bulks list process, in the context of obesity and osteoporosis.
Does this mean MOTS-c is approved for weight loss?
No. It is not an FDA-approved drug product for any use. A recommendation about compounding eligibility is not an approval and not evidence of effectiveness.
Why is MOTS-c marketed for energy and longevity?
Those claims run well past the reviewed context. Ask any clinic making them which human study supports that use.
Finding licensed care
If you want to talk to someone who can actually evaluate your situation, start with a licensed clinic. We list clinics by city and publish what we verified about each one, with the date we verified it.
Clinics we list: New York, NY, Charlotte, NC, Columbus, OH, Oklahoma City, OK